REG - AstraZeneca PLC - Result of AGM

AstraZenecaAnnouncement

18/05/2018 17:30

RNS Number : 6378O
AstraZeneca PLC
18 May 2018
 

18 May 2018 17:30 BST
 
Results of Annual General Meeting held on 18 May 2018
 
AstraZeneca PLC announced the results of the voting at its Annual General Meeting (AGM) today. As proposed in the Notice of AGM, all Resolutions were decided by poll vote. Resolutions 1 - 8 were passed as ordinary resolutions and resolutions 9 - 13 were passed as special resolutions.
 




 


RESOLUTION


VOTES FOR


% OF VOTES CAST


VOTES AGAINST


% OF VOTES CAST


VOTES CAST IN TOTAL


TOTAL VOTES CAST AS A % OF ISSUED SHARE CAPITAL


VOTES WITHHELD




1


To receive the Company's Accounts, the Reports of the Directors and Auditor and the Strategic Report for the year ended 31 December 2017
 


975,352,556


99.97


286,020


0.03


975,638,576


77.03%


2,190,628




2


To confirm dividends
 


973,207,907


99.66


3,276,414


0.34


976,484,321


77.09%


1,345,238




3


To reappoint PricewaterhouseCoopers LLP as Auditor
 


975,991,837


99.92


823,912


0.08


976,815,749


77.12%


1,010,316




4


To authorise the Directors to agree the remuneration of the Auditor
 


975,217,035


99.83


1,642,984


0.17


976,860,019


77.12%


966,821




5a


To re-elect Leif Johansson as a Director
 


965,159,252


98.78


11,893,311


1.22


977,052,563


77.14%


777,040




5b


To re-elect Pascal Soriot as a Director
 


976,561,635


99.96


423,451


0.04


976,985,086


77.13%


840,934




5c


To re-elect Marc Dunoyer as a Director
 


966,288,665


98.93


10,404,129


1.07


976,692,794


77.11%


1,131,405




5d


To re-elect Geneviève Berger as a Director
 


969,536,507


99.27


7,178,145


0.73


976,714,652


77.11%


1,111,156




5e


To re-elect Philip Broadley as a Director
 


976,367,428


99.97


321,290


0.03


976,688,718


77.11%


1,137,091




5f


To re-elect Graham Chipchase as a Director
 


881,989,499


92.80


68,391,901


7.20


950,381,400


75.03%


27,446,864




5g


To elect Deborah DiSanzo as a Director
 


976,385,364


99.97


318,846


0.03


976,704,210


77.11%


1,122,657




5h


To re-elect Rudy Markham as a Director
 


963,170,539


98.61


13,530,376


1.39


976,700,915


77.11%


1,129,638




5i


To elect Sheri McCoy as a Director
 


976,377,268


99.97


302,558


0.03


976,679,826


77.11%


1,148,061




5j


To elect Nazneen Rahman as a Director
 


975,580,506


99.89


1,085,775


0.11


976,666,281


77.11%


1,161,656




5k


To re-elect Shriti Vadera as a Director
 


974,721,822


99.80


1,938,806


0.20


976,660,628


77.11%


1,168,365




5l


To re-elect Marcus Wallenberg as a Director
 


728,805,452


77.48


211,832,691


22.52


940,638,143


74.26%


37,189,833




6


To approve the Annual Report on Remuneration for the year ended 31 December 2017
 


616,320,491


65.08


330,706,327


34.92


947,026,818


74.77%


30,798,857




7


To authorise limited political donations
 


951,435,712


97.85


20,941,516


2.15


972,377,228


76.77%


5,450,018




8


To authorise the Directors to allot shares
 


879,235,003


90.02


97,511,636


9.98


976,746,639


77.11%


1,081,345




9


To authorise the Directors to disapply pre-emption rights
 


964,350,714


98.99


9,859,917


1.01


974,210,631


76.91%


3,617,671




10


To authorise the Directors to further disapply pre-emption rights for acquisitions and specified capital investments
 


948,470,583


97.36


25,722,825


2.64


974,193,408


76.91%


3,633,732




11


To authorise the Company to purchase its own shares
 


964,157,201


98.76


12,138,730


1.24


976,295,931


77.08%


1,532,147




12


To reduce the notice period for general meetings
 


887,046,924


91.22


85,341,411


8.78


972,388,335


76.77%


5,438,953




13


To adopt new Articles of Association


962,268,146


99.00


9,709,546


1.00


971,977,692


76.74%


5,848,152




 
AstraZeneca is pleased to have received shareholder support for all resolutions proposed at the AGM, but is disappointed with the lower level of support received for its Annual Report on Remuneration for the year ended 31 December 2017.



AstraZeneca engaged with its major shareholders during 2017 and is disappointed that enhancements made to Remuneration Report disclosures and changes to the operation of the annual bonus scheme in response to shareholder feedback have not significantly improved the voting result.



The Remuneration Committee has already engaged with a number of shareholders to understand the reasoning behind their decisions not to support the Remuneration Report and will continue to engage with shareholders during 2018 to determine how best to address their concerns.
 
Issued capital
As at 16 May 2018, the number of issued shares of the Company was 1,266,635,735 ordinary shares, which was the total number of shares entitling the holders to attend and vote for or against all of the resolutions at the AGM. In accordance with the Company's Articles of Association, on a poll every member present in person or by proxy has one vote for every share held.
 
Adrian Kemp
Company Secretary, AstraZeneca PLC
18 May 2018
 
 
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
 
For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca.
 




Media Relations


 


 




Karen Birmingham


UK/Global


+44 203 749 5634




Rob Skelding


UK/Global


+44 203 749 5821




Matt Kent


UK/Global


+44 203 749 5906




Gonzalo Viña


UK/Global


+44 203 749 5916




Jacob Lund


Sweden


+46 8 553 260 20




Michele Meixell


US


+1 302 885 2677




 


 


 




Investor Relations


 


 




Thomas Kudsk Larsen


 
 


+44 203 749 5712




Craig Marks


Finance; Fixed Income; M&A


+44 7881 615 764




Henry Wheeler


Oncology


+44 203 749 5797




Mitchell Chan


Oncology; Other


+1 240 477 3771




Christer Gruvris


Brilinta; Diabetes


+44 203 749 5711




Nick Stone


Respiratory; Renal


+44 203 749 5716




US toll free


 


+1 866 381 7277




 



This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RAGGGUUGAUPRGQR